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T h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o r s( P P A R )α, β/δ,a n dγ are ligand-activated nuclear receptors involved in a number
of physiological processes, including lipid and glucose homeostasis, inﬂammation, cell growth, diﬀerentiation, and death. PPAR
agonists are used in the treatment of human diseases, like type 2 diabetes and dyslipidemia, and PPARs appear as promising
therapeutic targets in other conditions, including cancer. A better understanding of the functions and regulation of PPARs
in normal and pathological processes is of primary importance to devise appropriate therapeutic strategies. The ubiquitin-
proteasome system (UPS) plays an important role in controlling level and activity of many nuclear receptors and transcription
factors. PPARs are subjected to UPS-dependent regulation. Interestingly, the three PPAR isotypes are diﬀerentially regulated by
the UPS in response to ligand-dependent activation, a phenomenon that may be intrinsically connected to their distinct cellular
functions and behaviors. In addition to their eﬀects ongene expression, PPARs appear to aﬀect protein levels and downstream
pathways also by modulating the activity of the UPS in target-speciﬁc manners. Here we review the current knowledge of the
interactions between the UPS and PPARs in light of the potential implications for their eﬀects on cell fate and tumorigenesis.
Copyright © 2008 Davide Genini et al. Thisisan open access articledistributedunder theCreative CommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Despite the everyday progress in understanding the genetic
and molecular bases of cancer, this disease still strikes
millions of people worldwide. The quest for new targets
and more eﬀective therapeutics is currently a major driving
force in cancer research. Multiple mutations that aﬀect
critical cellular pathways lead to uncontrolled proliferation,
increased survival, and block of diﬀerentiation in cancer cells
[1]. Several cellular pathways (e.g., cell surface receptors,
signal transduction pathways, apoptosis, angiogenesis, tran-
scription, chromatin regulation, and proteasome-mediated
degradation) have provided relevant targets and oppor-
tunities for development of clinically useful therapeutics
[1]. Unfortunately, targeting each of these major pathways
individually may not be suﬃcient. Extensive cross-talks
occur between regulatory pathways and it is not unlikely
that the same proteins play multiple roles in diﬀerent
processes. The peroxisome proliferator-activated receptor
(PPAR) subfamily of nuclear receptors may represent a
prime example of proteins interacting with multiple cellular
pathways and exerting diverse and sometime apparently
contrasting functions. Here, we review how PPARs interact
with the ubiquitin-proteasome system (UPS), which is the
major cellular system responsible for protein turnover, and
how these two systems might reciprocally aﬀect each other
activity and functions.
2. THE UBIQUITIN-PROTEASOME SYSTEM
Ubiquitin is a 76-amino acid polypeptide that is post-
transcriptionally linked to proteins via a covalent linkage to2 PPAR Research
oneormultiplelysineresidues[2].Severalproteinsincluding
cell surface receptors, cell cycle regulators, and transcrip-
tion factors are ubiquitinated and protein ubiquitination
aﬀects many cellular processes including proliferation, cell
cycle progression, DNA damage repair, and cell death [2].
Ubiquitination is a regulatory signal that aﬀects the fate and
functionofproteins.Ubiquitinationregulatesmainlyprotein
turnover directing ubiquitinated proteins to proteasome-
mediated proteolysis. Other nonproteolytic functions, like
control of protein-protein interactions, cellular localization,
and catalytic activity, are emerging [2] .T h ep r o t e a s o m ei s
a multicatalytic complex that comprises a 20S core with
proteolytic activity and a 19S subunit that recognizes poly-
ubiquitinatedproteins,unfoldsthem,andpassesintothe20S
catalytic core for degradation. Ubiquitination is catalyzed by
threetypesofenzymes,calledE1,E2,andE3[2,3].Ubiquitin
is ﬁrst activated by an E1 ubiquitin-activating enzyme in
an ATP-dependent reaction. The activated ubiquitin is then
transferred to an E2 ubiquitin-conjugating protein (UBC).
Finally, E3 ubiquitin-ligases, which are the most critical
enzymes in the process, catalyze the transfer and covalent
attachments of the activated ubiquitin to the target protein.
In human cells, a single E1 and about 60 E2 enzymes have
been identiﬁed, while there are approximately a thousand
E3 enzymes, which ensure a high degree of substrate
speciﬁcity to the system [2, 3]. E3 enzymes are split in
two major subfamilies: the Ring-H2 and the HECT domain
proteins. The human genome contains also more than 70
deubiquitinating enzymes (DUBs) that remove ubiquitin
chains from ubiquitinated proteins and can rescue them
from proteasomal degradation [4].
Protein ubiquitination is a highly dynamic process
and ubiquitination-deubiquitination cycles can serve to
rapidly modulate protein level and function [4]. Ubiquitin
and proteasomal components play an important role in
transcription [5, 6]. Ubiquitin ligases and proteasomal
subunits are present as integral components of transcription
regulatory complexes [5, 6]. Histones, the main component
of chromatin, are ubiquitinated and the process aﬀects
chromatin remodeling and transcription [6, 7]. RNA poly-
merase II is also directly regulated by ubiquitination [6, 8].
Moreover, the UPS regulates the abundance, activity, and
subcellular localization of many transcription factors [5, 6].
Transcription factors are ubiquitinated and degraded by the
proteasome and, paradoxically, the process is often essential
for their transactivating ability [6]. In fact, transcription
activation and degradation domains of transcription factors
often overlap [6]. In addition, mono-ubiquitination (i.e.,
addition of single ubiquitin tag to a protein) can act as a
post-translational modiﬁcation that modulates activity of
transcriptionfactorsandregulatestranscriptioneﬃciencyby
nonproteolytic mechanisms [6]. Degradation of inhibitors
of transcription factors is also often required to release
active transcription factors. For example, activation of the
transcription factor NF-κB is controlled by a signaling
cascade based on multiple ubiquitination and proteasome-
dependent events [6].
Alterations of the UPS are frequent in cancer. They are
mainlyduetolossorgainoffunctionofspeciﬁccomponents
of the UPS and alterations of UPS substrates, like oncogene
and tumor suppressor gene products, which become less
or more susceptible to proteasomal-dependent degradation
[9]. Tumor suppressor proteins are often the targets of UPS
alterations. The human papillomavirus (HPV), a cause of
cervical cancer, encodes two oncogenic proteins, E6 and
E7. These viral proteins promote degradation of the tumor
suppressor p53 via ubiquitination by the E6-associated pro-
tein (E6-AP) E3 ubiquitin ligase [10]. HDM2 is another E3
ubiquitin ligase that targets p53 to proteosomal degradation
[11].AberrantexpressionofHDM2isfoundinmanyhuman
cancers [12]. Single nucleotide polymorphism in the HDM2
promoterleadingtoHDM2overexpressionhasbeenrecently
associated to the development of sporadic and hereditary
cancers [13]. The E3 ubiquitin ligase Skp2 is responsible
for ubiquitination of the cell cycle inhibitor and tumor
suppressor p27 [14]. Skp2 overexpression is observed in
cancer cells leading to degradation and inactivation of this
tumor suppressor protein [15]. Oncogenic proteins are also
aﬀected by alterations of UPS components. The E3 ubiquitin
ligase encoded by the von Hippel-Lindau gene (pVHL)
mediates the ubiquitination and degradation of the hypoxia-
inducible transcription factor HIF-1α [16, 17]. Mutations
in pVHL gene predispose patients to renal cell carcinoma
and other cancers. In these tumors, the level of HIF-1α is
increased resulting in a potent oncogenic and angiogenic
stimulus.
Due to the unique mechanism of cleavage at the
proteolytic active sites, selective proteasome inhibitors have
been synthesized and some, like bortezomib (Velcalde,
PS341), have undergone clinical evaluation as anticancer
agents [18]. Bortezomib is a peptide boronate proteasome
inhibitor that blocks the chymotryptic activity of the 26S
proteasome [18]. The anticancer eﬀect of bortezomib is
likely to be achieved through its inhibitory eﬀects on protein
degradation and modulation of important cellular pathways,
including inhibition of the NF-κBp a t h w a y[ 18]. Bortezomib
is currently approved for clinical use for treatment of
multiple myeloma. Clinical trials with bortezomib and
second generation proteasome inhibitors as single agents
or in combination with other chemotherapeutic agents are
ongoing in various tumor types [18].
3. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS
PPARs emerged in the nineties as nuclear receptors regulat-
ing transcription of genes involved in metabolic processes
like lipid and glucose homeostasis [19, 20]. Later, PPARs
have found to be implicated in many physiological and
pathological processes [20]. PPARs belong to the nuclear
hormone receptor super-family, which is one of the largest
families of transcriptional regulators in the human genome
with more than 40 distinct nuclear receptors [21]. Nuclear
receptors bind small lipophilic molecules, such as steroid
hormones, vitamins, and fatty acid derivatives, and function
as ligand-activated transcription factors, interacting with
speciﬁc DNA sequences (i.e., hormone response elements,
HRE) in target genes and stimulating their transcriptionDavide Genini et al. 3
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Figure 1: Domain structure of PPARδ and truncated forms of the receptor. AF-1, N-terminal ligand-independent activation function 1 (aa
1–70).DBD,DNAbindingdomain(aa71–136).Hinge,ﬂexiblehingeregion(aa137–167).LBD,ligand-bindingdomain(aa168–431).AF-2,
C-terminal ligand-dependent activation function-2 (aa 432–441). The position of the mutations (K204R, K224R, and K229R) introduced in
the region 204–235 is shown.
[21]. Thus, nuclear receptors provide a direct link between
small lipophilic signaling molecules present in the cells or
their environment and the cellular transcriptional machin-
ery, turning on speciﬁc subsets of genes containing the
appropriate HRE and inducing complex cellular responses
[21, 22]. The nuclear receptor super-family includes the
steroid hormone receptors (i.e., estrogen, progesterone,
androgen, and glucocorticoid receptors) and receptors for
nonsteroidal hormones [21–23]. The latter include the
PPARs, vitamin D (VDR), and retinoic acid (RAR) receptors
[21, 23]. The ligands of most nonsteroidal receptors are
dietary fatty acids or generated locally by lipid metabolism
within the target cell or tissue, while steroid and thyroid
hormones are produced by distant endocrine organs and
released in the blood [21, 22].
Nuclear receptors exhibit a characteristic modular struc-
ture comprising an N-terminal domain with the ligand-
independent activation function domain (AF-1), a DNA
binding domain (DBD), and a C-terminal domain contain-
ing the ligand binding (LBD), and the ligand-dependent
transactivation (AF-2) domain [23]. The DBD contains
two zinc ﬁnger modules and determines the DNA binding
speciﬁcity of the receptors. The LBD is involved in homo-
and heterodimerization and interaction with cofactors [23,
24]. The structure of the LBD is highly conserved among
nuclearreceptors,comprisingalargehydrophobiccavitythat
accommodates the ligand. Variations of the size and shape
of the ligand binding pocket ensure ligand speciﬁcity among
receptors [23, 24]. Ligand-binding induces a conformational
remodeling of the LBD that exposes surfaces required for
interaction with coactivators and aﬀects the aﬃnity of
the receptors for corepressors [23, 24]. The nonsteroidal
receptors are found primarily in the cell nucleus and are
bound to HRE as heterodimers with the retinoic X receptor
(RXR) [19, 23]. These receptors can aﬀect both positively
and negatively transcription of target genes with the LBD
mediating alternatively transcriptional activation or repres-
sion, although the mechanisms of transrepression by PPARs
are still poorly understood [25]. Transcriptional repression
is due to recruitment of corepressors, like NCoR/SMART,
by the unliganded and DNA-bound receptor and formation
of multiprotein complexes containing histone deacetylases
and other chromatin remodeling enzymes [23, 25]. In the
presence of ligands, corepressor complexes are released and
replaced by coactivators, like SRC1 and CBP-p300, thus
switching on transcription [23, 25]. Transcriptional acti-
vation is associated with histone modiﬁcations, chromatin
remodeling, and assembly of the transcription initiation
complex. Thus, transcriptional activation and repression by
nuclear receptors are very dynamic processes involving the
formation of protein complexes in which multiple coactiva-
tors and corepressors need to be rapidly exchanged [25–27].
The UPS is perhaps the major system controlling the assem-
bly and turnover of these regulatory complexes ensuring
their timely interaction with the transcriptional machinery
[26]. Ubiquitin and proteasome components are associated
with corepressor and coactivator complexes recruited by
nuclear receptors [25, 26]. Most nuclear receptors, including
thyroid hormone, estrogen, glucocorticoids receptor, RAR,
and RXR receptors, as well as coactivators, corepressors,
and general components of the transcription machinery are
ubiquitinated and degraded by the proteasome [26, 28].
PPARs have the typical modular structure of the nuclear
hormone receptors with a poorly characterized N-terminal
domain with putative ligand-independent AF-1 function,
a central DNA-binding domain (DBD), and a C-terminal
ligand binding (LBD) and ligand-dependent AF-2 domain
(Figure 1)[ 19, 23]. However, despite the high sequence and
structural homology, the three PPAR isotypes have distinct
ligandspeciﬁcity,functions,andbehaviors[19,20].PPARαis
a key regulator of energy homeostasis and plays a major role
in lipid metabolism and glucogenesis. PPARα is expressed in
tissues with signiﬁcant fatty acid and cholesterol catabolism,
like brown adipose tissue, liver, kidney, intestine, heart, and
skeletal muscle [29]. PPARγ exists in two isoforms (γ1a n d
γ2) that diﬀer only at the N-terminus. PPARγ2i sp r e s e n ta t4 PPAR Research
high levels in adipose tissue, whereas PPARγ1 expression is
broader and is present in gut, brain, vascular cells, immune
cells, and retina [30]. PPARγ plays a role in adipocyte
diﬀerentiation, glucose metabolism, and lipid homeostasis,
and participates in monocyte/macrophage diﬀerentiation
[30]. Moreover, PPARγ inﬂuences fatty acid storage in the
adipose tissue and is implicated in insulin resistance and
atherosclerosis [30]. PPARδ is ubiquitously expressed with
high levels in colon, skin, and brain [20]. PPARδ also func-
tions in processes linked to lipid metabolism, like fatty acid
catabolism, cholesterol eﬄux, lipid uptake in macrophages,
and preadipocyte diﬀerentiation [31]. This nuclear receptor
plays also a role in placental and gut development, embryo
implantation, tissue injury, and wound healing [20, 32].
PPARs possess a broad ligand-binding cavity that allows
binding of a wide range of synthetic and natural lipophilic
compounds[19].Medium-andlong-chainunsaturatedfatty
acids (e.g., linoleic acid), conjugated and oxidized fatty
acids (e.g., phytanic acid), and eicosanoids bind to PPARα
[19]. Fibrates, like bezaﬁbrate, fenoﬁbrate, and cloﬁbrate,
which are used for the treatment of dislipidemias and
cardiovascular diseases, are selective PPARα agonists [29].
PPARγ binds to long-chain fatty acids, prostaglandin J2
(PG J2), and other eicosanoids [19]. Synthetic PPARγ
agonists, such as pioglitazone and rosiglitazone, are insulin
sensitizers used to treat type 2 diabetes [30]. PPARδ has high
aﬃnity for prostaglandin I2 (PGI2), fatty acids, and synthetic
compounds [19, 31].
Beside their metabolic functions, PPARs have an impor-
tant role in inﬂammation. PPARα and PPARγ agonists can
ameliorate chronic inﬂammatory conditions, such as athro-
sclerosis, arthritis, and inﬂammatory bowel disease [20, 29,
30]. PPARs repress genes of the inﬂammatory response
pathway,suchascytokines(TNFα,IL-1β,IL-6),celladhesion
molecules (MMPs), and other proinﬂammatory molecules
(iNOS) [25]. These eﬀects are mediated in large part by the
ability of PPARs to antagonize other transcription factors,
like AP-1, STAT1, and NF-κB, which have proinﬂammatory
functions [25]. Diﬀerent mechanisms have been proposed
to explain the phenomenon of transrepression by PPARs,
including sequestration of limiting cofactors, direct physical
interaction, and antagonism between PPARs and other
transcription factors, and promoter-speciﬁc block of core-
pressor/coactivator exchange by PPARs in selected target
genes[24,25].Thelatterinvolvesablockoftheubiquitinand
proteasome-dependent processing of corepressor complexes
as in the case of PPARγ-mediated repression of proin-
ﬂammatory NF-κBt a r g e tg e n e s[ 25]. PPARγ and PPARα
can also interact physically with NF-κB and c-Jun blocking
transcriptional activation [33, 34]. Reciprocally, NF-κBa n d
c-Jun can repress PPARγ and PPARα-induced transcription,
respectively,byinhibitingthebindingtoPPREintargetgenes
[33–35]. Also PPARδ has a role in inﬂammation controlling
expression of proinﬂammatory genes in macrophages in a
ligand-dependent manner [31]. Unliganded PPARδ binds to
corepressor molecules including Bcl-6, which is a repressor
of inﬂammatory gene expression [31, 36]. Ligand binding
re-leasesthecorepressorcomplexesresultingintranscription
of PPARδ target genes. At the same time, PPARδ-bound
Bcl-6 is also released and is free to repress its own target
genes suppressing the inﬂammatory response [31, 36].
Paradoxically, PPARδ knockout has the same eﬀects of the
agonists on the expression of Bcl-6 target genes since it also
leads to release the transcriptional repressor [36].
The involvement of PPARs in carcinogenesis has been
widely discussed, although it is still controversial whether
the diﬀerent isotypes either favor or inhibit tumorigenesis
[37, 38]. This may still represent a major concern for devel-
oping PPAR-targeted therapeutics for clinical applications
because of the potential risk of promoting tumorigenesis as
indicated by studies in rodents [39]. PPARs are expressed in
several human cancers and PPAR ligands have been shown
to modulate tumor growth [37, 38]. Inactivating muta-
tions, deletions and chromosomal translocations of PPARγ
have been found in various cancers pointing to a tumor
suppressor role of this nuclear receptor [40–42]. PPARγ
ligands promote diﬀerentiation, growth arrest, and death of
cancer cells in vitro [38]. PPARγ ligands reduce growth of
human tumor xenografts and spontaneous and carcinogen-
induced tumors in rodents [38]. PPARα is also expressed in
various tumors and cancer cell lines [43, 44]. Activation of
PPARα in cancer cells inhibits proliferation and suppresses
metastatic potential [45–47]. PPARα ligands have shown
antitumoractivityalsoinmurinemodels[46,48,49].PPARδ
participates in a number of important pathways controlling
adhesion, proliferation, diﬀerentiation, and survival [37].
Unlike the other isotypes, PPARδ has been shown to prevent
apoptosis and induce cell growth in normal cell types,
like primary mouse keratinocytes, preadipocytes, vascular
smooth muscle cells, hepatic stellate cells [37]. Consistent
with an antiapoptotic role, PPARδ increases the expression
of antiapoptotic genes and activates prosurvival signaling
pathways in keratinocytes [50]. PPARδ agonists stimulate
proliferationandsurvivalofcancercellsinvitroandpromote
tumor growth in mice [51–57]. PPARδ is a downstream
target of β-catenin/T cell factor-4, which is central in colon
cancer pathogenesis and regulates other cancer-promoting
genes like c-myc and cyclin D1 [58]. Cyclooxygenase-2
(Cox-2) modulates PPARδ activity and nonsteroidal anti-
inﬂammatory drugs that have chemopreventive eﬀects in
colon cancer inhibit PPARδ activity and expression [58–60].
Cox-2 is frequently upregulated in cancer and preneoplastic
lesions,andCox-2productslikePGI2 actasselectiveagonists
of PPARδ [58–60]. To further support a protumorigenic
role of PPARδ,P P A R δ expression is elevated in cancers, like
colorectal, endometrial, and head and neck cancers [58, 59,
61]. Additional evidence pointing to a tumor promoting
function of PPARδ comes from experiments in mice where
disruptionofPPARδ decreasedtumorigenicityofcancercells
in nude mice and PPARδ activation increased tumor growth
[55, 57, 62].
Despite this large body of evidence, some controversial
results in animal experiments cast doubts both on the anti-
and protumorigenic activities of PPARs [37, 38]. Exper-
iments in rodents have shown increased frequency and
enhanced tumor growth by PPARγ agonists [38, 63, 64].
Similar contradictory data have been reported for PPARα,Davide Genini et al. 5
wherebyprolongedadministrationofPPARαagonistscaused
hepatocarcinogenesis in rats and mice [65]. The frequency
of intestinal tumors also increased in PPARδ knockout mice
[66, 67] or decreased upon treatment of the animals with
PPARδ ligands [68]. These contradictory results between
cellular and animal models and diﬀerent animal models
suggest that the function of these nuclear receptors is more
complex than that has been assumed so far and may depend
heavily on cell and tissue context, cross-talks with multiple
signaling pathways and noncell autonomous mechanisms.
A hint to this complexity is given by recent studies of
the role of PPARs in tumor angiogenesis. In addition to
cancer cell-autonomous eﬀects, PPARs aﬀect strongly tumor
angiogenesis and inﬂammation, two processes that have a
critical role in tumor pathogenesis and progression. PPARγ
and PPARα agonists have anti-inﬂammatory properties,
which may contribute greatly to their in vivo antitumor
activity under certain circumstances. PPARγ ligands are also
potent angiogenic inhibitors [69, 70]a n dP P A R α agonists
suppress VEGF production, endothelial cell proliferation,
and tumor growth in mice [48, 49]. PPARδ activation
stimulates VEGF production in mice, which at least in
part had an autocrine prosurvival eﬀect on cancer cells
[71]. PPARδ has been recently identiﬁed as a critical node
in a tumor angiogenic network linking angiogenesis to
inﬂammation and carcinogenesis [72]. Knockout of PPARδ
in host tissues but not in tumor cells reduced tumor growth
by impairing angiogenesis [72]. Interestingly, the in vivo
antitumor activity of PPARα agonists also depended heavily
on the eﬀects of host endothelial and stromal cells rather
than cancer cells blocking angiogenesis and inﬂammation
[48, 49]. Paradoxically, PPARα knockout impaired tumor
growth in mice, because it resulted in a strong inﬂammatory
response and production of anti-angiogenic factors, like
TSP-1 and endostatin [73]. This paradoxical response is
similar to the eﬀects of PPARδ on inﬂammatory gene
expression in macrophages, where both receptor activation
and knockout suppressed expression of a subset of target
genes [31, 36]. This dual mode of regulation of gene
expression, whereby ligand- dependent and independent
mechanisms lead to transrepression, derepression, or trans-
activation of distinct subsets of genes, seems a common
theme for these nuclear receptors and needs to be taken into
accountwhenexaminingtheirfunctionsinphysiologicaland
pathological processes.
4. THE UBIQUITIN-PROTEASOME SYSTEM
AND PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS
4.1. UPSandcontrolofPPARturnover
Important factors to consider when studying the multiple
and complex functions of PPARs are their connections with
othercellularsystemsandhowtheseinteractionsreciprocally
impact on each system activity. Recent reports suggest
that the activity of PPARs is linked in many ways to the
UPS [28]. All three PPARs are short-lived proteins that
undergo ubiquitination and proteosomal degradation and
the UPS is mainly responsible for the turnover of these
nuclear receptors [28]. However, the three PPAR isotypes
have diﬀerent behaviors with respect to ligand-dependent
receptor turnover. PPARγ undergoesnegativeautoregulation
upon agonist binding. PPARγ is ubiquitinated and degraded
by the proteasome in a negative feedback loop that probably
serves to attenuate receptor-mediated gene transactivation
[74]. PPARα turnover is controlled by ligands in a slightly
diﬀerent manner. Instead of enhancing ubiquitination and
degradation, PPARα ligands prevent ubiquitination and lead
to increased stability of the receptor [75]. The protective
eﬀect of the ligand, however, is maximal during the ﬁrst 3
hours of exposure to the ligand and the receptor is then
rapidly degraded [75].
We have recently examined the ligand-dependent
turnover of PPARδ and the role of the UPS in this process
[76]. Our study revealed interesting diﬀerences between
PPARδ and other PPAR isotypes with respect to ligand-
dependent receptor turnover and interaction with the UPS.
We found that PPARδ, like other nuclear receptors, is
ubiquitinated and rapidly degraded by the proteasome [76].
Brief incubation of cells expressing both endogenous and
recombinant PPARδ with proteasome inhibitors led to rapid
accumulation of the receptor in cell nuclei. Interestingly, in
the presence of proteasome inhibitors, PPARδ was transcrip-
tionally competent as shown by luciferase reporter assays
and assessment of endogenous target genes by RT-PCR [76].
Thus, PPARδ was diﬀerent from other nuclear receptors,
including the estrogen, androgen, thyroid hormone, and
retinoic acid receptors, whose transcriptional activity is
reduced by proteasome inhibitors [26]. Furthermore, while
in the absence of ligands PPARδ had a very short half life
(∼30 minutes), the addition of ligand increased considerably
the receptor half life [76]. The eﬀects of the synthetic
and natural ligands were rapid with an increase of PPARδ
protein level within 4 hours upon addition to the cell culture
medium. The receptor level remained high as long as the lig-
ands were present [76]. Removal of the ligands was followed
by rapid reversal with return to the baseline level within
few hours. Once again, PPARδ behavior was unique among
nuclear receptors, whose turnover is generally accelerated
by their own ligands [26, 77]. The progesterone receptor,
thyroid receptor, estrogen receptor, RAR, and RXR all show
ligand-dependent increase of degradation associated with
transcriptional activation [26, 77]. The direct consequence
of these events is a rapid decrease of the receptor half life
and switching-oﬀ the transcriptional response. Only vitamin
D3 receptor is known to be stabilized by the ligand with
a similar kinetics [78]. As mentioned above, PPARγ is also
rapidly degraded upon exposure to ligands [74]a n dP P A R α
is stabilized only transiently by ligands [75]. Further work
demonstrated that ligand-induced stabilization of PPARδ
was due to a selective block of receptor ubiquitination
[76]. This ubiquitination block depended on the continuous
presence of the ligand, was rapidly reversed after removal of
the ligand, and was due to the direct interaction of the ligand
withthereceptor[76].DisruptionoftheLBDinPPARδ/Tr1-
299 abolished the eﬀect of the ligand on ubiquitination and
proteolysis, although the truncated form of the receptor6 PPAR Research
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Figure 2: Ubiquitination of truncated and mutated forms of PPARδ. (a) U2OS cells were transfected with HA-ubiquitin expressing vector
along with wild type His-PPARδ or truncated forms of the receptor (PPARδ/Tr1-204, Tr1-235 and Tr1-299). After 24 hours, cells were
incubated overnight with vehicle or the PPARδ ligand GW501516 (5μM) and subsequently all samples were incubated with 10μMt h e
proteasome inhibitor PS341 for 4 hours. His-tagged wild type and truncated PPARδ were pulled-down with nickel aﬃnity gel under
denaturing conditions. PPARδ was detected in pull-down fractions using an anti-His antibody and ubiquitinated proteins with an anti-
HA antibody. (b) U2OS cells were transfected with HA-ubiquitin vector along with the indicated PPARδ expressing vectors. PPARδ/Tr1-235
had wild type sequence or the indicated double or triple mutations (K204R, K224R and K229R). Cells were treated and analyzed as above.
was still ubiquitinated and degraded by the proteasome
[76]. Thus, binding of the ligand to the LBD induced a
conformational change that, in addition to allowing receptor
trans-activation, blocked the interaction of PPARδ with an
ubiquitin ligase or, alternatively, promoted binding of a
deubiquitinating enzyme.
Using site-directed mutagenesis,we investigated further
the role of distinct PPARδ domains in the ligand-dependent
regulation of receptor turnover [76]. This analysis revealed
additional diﬀerences between PPARδ and other PPAR iso-
types. Mutations in the DBD of PPARδ reduced the eﬀect of
ligands on receptor ubiquitination [76]. This suggested that
the ligand acted preferentially on the DNA-bound receptor
preventing its ubiquitination. Interestingly, mutations in
DBD of PPARγ did not aﬀect ligand-dependent turnover,
indicating that DNA binding was not a prerequisite for
ligand-induced degradation of this receptor [74]. On the
other hand, we showed that the AF-2 domain of PPARδ
was not required for ligand-induced block of ubiquitination,
indicating that the eﬀect was independent of coactivator
binding [76]. For most nuclear receptors, the transactivating
function is linked to proteolytic degradation and mutations
in the transactivating domain aﬀect also receptor ubiquiti-
nation and proteolysis [77]. The AF-2 domain of PPARγ has
a similar role and mediates ligand-induced degradation of
the receptor [74]. For PPARγ and other nuclear receptors,
conformationalchangesinducedbytheligandsmayfavorthe
concomitant interaction with coactivators and components
of the UPS. Overexpression of transcriptional coactivators
ledalsotoadecreaseofPPARαlevelinthepresenceofligand,
showing that the interaction with coactivators via the AF-2
domain promoted proteolysis of the α isotype [79]. Thus,
for PPARα the initial stabilization is probably followed by
the recruitment of coactivators along with other factors that
trigger proteolysis of the receptor. In contrast, in the case of
PPARδ we showed that transactivation and receptor ubiq-
uitination are functionally separated [76]. The absence of a
link between these two processes allows independent control
of receptor transactivation and ubiquitination upon ligand
bindingandmaybeaprerequisitetoavoidrapiddegradation
and sustain its transcriptional activity once it is engaged
in transcriptional activation complexes. Further analysis of
PPARδ mutantsindicatesthattheregionbetweenaminoacid
204 and 235 may play a role in controlling ubiquitination
and proteolytic degradation of the receptor (Figure 1). This
region has a poor secondary structure, forms a loop exposed
to the surface, and may be in an environment prone to ubiq-
uitination [80, 81]. In addition, the region is quite diverse
betweenthePPARisotypes,possiblyexplainingthedivergent
responses in terms of ligand-dependent turnover. Pull-down
experiments showed that the truncated PPARδ/Tr1-235 was
ubiquitinated, while the shorter PPARδ/Tr1-204 was not
(Figure 2(a)). Diﬀerent scenarios can explain these results
and are underconsideration. The region between amino acid
204 and 235 may contain lysine residues that are the major
sites of ubiquitination of PPARδ. However, mutations of
the three lysines present in this region (K204R, K224R and
K229R) did not aﬀect ubiquitination of the PPARδ/Tr1-235
(Figure 2(b)). Thus, alternatively the region 204–235 may be
neededforthebindingofanubiquitinligaseorcofactorsthat
mediate the interaction of the receptor with the UPS.
Thus, evenif thePPAR isotypes arestructurallyverysim-
ilar, binding to speciﬁc ligands induces divergent responses
a sf a ra sr e c e p t o rt u r n o v e r .P P A R γ upon ligand binding
becomes ubiquitinated and prone to degradation, whereas
ligands prevent or delay ubiquitination and degradation ofDavide Genini et al. 7
PPARδ and PPARα. Most nuclear receptors exhibit negative
autoregulation upon interaction with the respective ligands
[26, 77]. Ligand-induced stabilization is a less common and
has been observed only for very few nuclear receptors. The
system in place for PPARδ may be geared to prevent both
accumulation of high levels of the receptor and its prolonged
activation [76]. Overactivity of PPARδ may be detrimental
to cells, perhaps due to its antiapoptotic and potentially
tumorigenic activity [32, 37]. The level of PPARδ is low
and constantly controlled via UPS-dependent proteolysis,
which may aﬀect greatly the ligand-independent functions
of the receptor like transrepression of other transcription
factor target genes. Under physiological conditions, the low
abundance and short half life of natural PPARδ ligands, like
PGI2, would contribute to keep the receptor in the unbound
state [32]. In the presence of high concentrations of ligands,
the DNA-bound and liganded PPARδ is protected from pro-
teasomal degradation by the inhibition of its ubiquitination
[76]. The stabilized DNA-bound receptor would be able to
transactivate target genes as long as enough ligand is present.
This would be consistent with the fact that in processes,
such as wound healing, inﬂammation, and cancer, PPARδ
levels seem to increase concomitantly with upregulation of
cyclooxygenase-2 and other enzymes for the production of
lipid metabolites capable of stabilizing and activating PPARδ
[32, 37, 55, 58, 59]. In the absence of this coordinated
increase of ligand and receptor levels, PPARδ might not be
able to act as antiapoptotic and growth-promoting factor.
How ligand-induced stabilization of PPARδ aﬀects ligand-
dependent interactions with other transcription factors
leading to transrepression or derepression of gene expression
is still unknown.
4.2. UPS,PPARs,andinteractionswith
othersignalingpathways
In addition to ligand-dependent receptor turnover, the UPS
is an important way to control PPAR activity in response to
upstream signal transduction pathways (Figure 3). Receptor
phosphorylation by cellular kinases can regulate both basal
and ligand-induced activity of PPARs as well as modulate
their protein level by indirectly controlling proteasome-
dependent degradation [82]. In colorectal cancer cells, the
polypeptidehormonegastrinpromotescellproliferationand
the eﬀect is associated with decreased PPARγ level. This was
mediated by phosphorylation of PPARγ involving the epi-
dermal growth factor receptor and ERK1/2 kinase leading to
increased PPARγ proteasome-mediated degradation [83]. In
fat cells IFN-γ treatment induces a rapid reduction of PPARγ
proteinlevel,whichisblockedbyproteasomeinhibitors[84].
On the other hand, there are instances in which PPARs
enhance stabilization or degradation of proteins by aﬀecting
their susceptibility to UPS-mediated degradation. Perhaps
thebestexampleofasignalingpathwayinwhichbothPPARs
and the UPS are implicated is the Wnt pathway. Suppression
of the canonical Wnt signaling is required for diﬀerentiation
ofpreadipocytesintoadipocytes.Theprocessisinpartmedi-
ated by PPARγ-induced degradation of β-catenin, which is
a central element in the Wnt pathway. Activation of PPARγ
Signaling pathway
Ligands
PPARs
UPS
Target gene
transcription
Target protein
stability
Cellular responses:
-Diﬀerentiation
-Proliferation
-Apoptosis
-Inﬂammation
-Angiogenesis
Figure 3: Interactions between PPARs and the ubiquitin-proteasome
system (UPS) aﬀect multiple cellular pathways. The UPS regulates
activity of PPARs by controlling receptor turnover in ligand
dependent and independent manners and aﬀecting the ability of
PPARs to regulate target gene transcription. Signaling pathways
can modulate PPAR activity by aﬀecting UPS-mediated turnover
(e.g., increased PPARγ d e gra d a t i o ni nr e s p o n s et ogr o wt hf a c t o r so r
hormones). PPAR can also aﬀect biological pathways and cellular
responses by increasing or decreasing susceptibility of proteins to
proteasomal degradation (e.g., enhanced degradation of β-catenin
and suppression of the Wnt pathway by PPARγ).
promotes degradation of β-catenin in glycogen synthase
kinase 3β (GSK3B)-dependent or independent manner [85,
86]. β-catenin mutations that inhibit degradation block
expression of a subset of adipogenic and PPARγ target genes
[85]. PPARγ-dependent degradation of β-catenin requires
an active APC-containing destruction-complex. Mutations
of the T cell factor/lymphocyte enhancer factor (TCF/LEF)
binding domain of β-cateninor of acatenin-binding domain
(CBD) within PPARγ block proteasomal degradation of β-
catenin [87]. The interaction between β-catenin and PPARγ
aﬀect their respective oncogenic and tumor suppressor func-
tion [87]. A functional APC was found to be required also
for PPARγ-mediated suppression of colon carcinogenesis
[88]. Activation of PPARγ induces degradation of cyclin D1,
which has a critical role in cell cycle regulation, along with
β-catenin in hepatocytes [89]. Reduced cyclin D1 protein
level was observed also in breast cancer cells upon PPARγ
activation by selective ligands and cyclin D1 downregulation
was blocked by inhibition of the proteasome [90]. However,
the ability of thiazolidinedione ligands to reduce β-catenin
and cyclin D1 levels might be in part PPARγ-independent
and determined by direct eﬀects of these compounds
on protein degradation [91, 92]. Beside the induction of8 PPAR Research
proteosomal degradation, activation of PPARγ has been
shown to increase the level of proteins by blocking their
proteolysis.ActivationofPPARγ inhumanhepatocarcinoma
cells inhibits proteosomal degradation of p27, a cyclin-
dependent kinase inhibitor, with consequent inhibition of
cell proliferation [93]. Similarly, PPARγ inhibits claudin 4
degradation resulting in urothelial cell diﬀerentiation [94].
In both cases, the increased protein level is probably due to
reduced ubiquitination. Interestingly, transcriptome analysis
of ovarian cancer cells exposed to a PPARγ agonist revealed
that PPARγ activation resulted in upregulation of several
genes involved in protein modiﬁcation and ubiquitination,
including many ubiquitin ligases and ubiquitin-conjugating
enzymes [95]. This ﬁnding may provide a plausible expla-
nation for the broad eﬀects that PPAR-γ agonists have on
protein ubiquitination and turnover and clearly deserves
further investigation [95].
PPARα agonists also enhance protein degradation. In
LPS-treated macrophages PPARα agonists enhance degra-
dation of inducible nitric oxide synthase (iNOS), reducing
nitric oxide (NO) production, which is an important media-
tor in inﬂammatory processes. PPARα agonists did not aﬀect
iNOS expression and proteasome inhibitors reversed the
eﬀect on iNOS protein levels, indicating that PPARα agonists
enhanceddegradationofthisproteinbytheproteasome[96].
PPARδ has been found to regulate ubiquitin C expression
and this has been linked to the modulation of protein
kinase Cα (PKCα) and attenuation of cell proliferation in
the skin. The level of PKCα was lower in the skin of PPARδ
wild-type mice treated with TPA compared to the skin of
PPARδ-null mice [97]. On the other hand, the amount
of ubiquitinated PKCα was lower in skin of TPA-treated
PPARδ-nullmicecomparedtowild-typemiceandinhibition
of the proteasome prevented TPA-induced downregulation
of PKCα. Thus, the eﬀects of PPARδ on cell proliferation
in the skin could be due to ubiquitin-dependent turnover
of PKCα that in turn modulated the activity of the PKCα-
dependent pathways [97].
Finally, the UPS is involved in the reciprocal regulation
of PPARs and other transcription factors. Activation of NF-
κB is achieved when the inhibitor IκB, which normally holds
NF-κB in the cytoplasm, is phosphorylated and recognized
by the E3-β-transducin repeat containing protein (β-TRCP).
Ubiquitinated IκB is degraded by the proteasome, allowing
NF-κB to translocate to the nucleus and induce gene
transcription[98]. NF-κBh a sac ri ti c a lr o l ei ni n ﬂ a m m a ti o n .
In experimental rat models of autoimmune myocarditis
stabilization and translocation of NF-κB were inhibited by
PPARγ-dependent expression of IκB[ 99]. Likewise, PPARα
activation induced IκB in aortic smooth muscle cells and
in human hepatocytes [100]. The transcription factor AP-1,
which is another key player in inﬂammation, interacts with
the PPARs and may be regulated in a similar combinatorial
manner by PPARs and the UPS [33, 34].
5. CONCLUSIONS
Here, we have presented the current evidence linking PPARs
and the UPS. Ubiquitination and proteasomal degradation
control the level and modulate the activity of PPARs in
many ways. Ligand binding and proteolytic degradation
aﬀect turnover and transcriptional activity of the PPAR
isotypes in distinct ways. PPARδ ubiquitination is selectively
blocked by agonist ligands ensuring the accumulation of
DNA-bound receptor engaged in transcriptional activation
complexes. The opposite is true for the other PPAR isotypes.
Distinct cellular pathways can exploit the UPS to modulate
PPAR turnover and activity aﬀecting their multiple func-
tions. Furthermore, PPARs can control the level of speciﬁc
proteins by modulating the activity of the UPS. This could
be mediated by their ability to control the expression of
componentsoftheUPS,likeubiquitinligases,orviaprotein-
protein interactions. Controlling turnover of the receptors,
the UPS can aﬀect also the ligand-independent functions of
PPARs. In this context, the control operated by the UPS on
n u c l e a rr e c e p t o rl e v e l sm i g h ta ﬀect their ability to modulate
activity of other transcriptional regulators. Increased pro-
teolysis might reduce PPAR levels and produce apparently
paradoxical responses with derepression or transrepression
of distinct subsets of genes as seen in certain PPAR knockout
experiments. The contribution of the multiple interactions
between PPARs and the UPS need to be taken in consider-
ation when examining the eﬀects of PPAR overexpression,
knock down or ligand-dependent activation on complex
biological processes, like inﬂammation, angiogenesis, and
tumorigenesis.
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